These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 26833487)
1. Get the GIST? An overview of gastrointestinal stromal tumours. Watson GA; Kelly D; Melland-Smith M; Gleeson J; McEntee G; Kelly CM; McCaffrey JA Ir J Med Sci; 2016 May; 185(2):319-26. PubMed ID: 26833487 [TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
4. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. Kondo T Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810 [TBL] [Abstract][Full Text] [Related]
5. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Gold JS; Dematteo RP Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179 [TBL] [Abstract][Full Text] [Related]
6. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
7. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
9. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460 [TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors]. Xu J; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353 [TBL] [Abstract][Full Text] [Related]
11. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors. Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973 [TBL] [Abstract][Full Text] [Related]
13. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525 [TBL] [Abstract][Full Text] [Related]
14. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. Rutkowski P; Magnan H; Chou AJ; Benson C BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076 [TBL] [Abstract][Full Text] [Related]
17. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568 [TBL] [Abstract][Full Text] [Related]
18. Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. Blay JY; Casali PG; Dei Tos AP; Le Cesne A; Reichardt P Oncology; 2015; 89(1):1-13. PubMed ID: 25720422 [TBL] [Abstract][Full Text] [Related]
19. GEIS guidelines for gastrointestinal sarcomas (GIST). Poveda A; García Del Muro X; López-Guerrero JA; Cubedo R; Martínez V; Romero I; Serrano C; Valverde C; Martín-Broto J; Cancer Treat Rev; 2017 Apr; 55():107-119. PubMed ID: 28351781 [TBL] [Abstract][Full Text] [Related]